- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00989443
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)
Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix (surgical act). A local treatment with the antiviral and anti-proliferative cidofovir would preserve the cervix of young subjects and reduce obstetrical morbidity induced by the conisation.
This clinical study is aimed at :
- evaluating the tolerance and safety of a cidofovir gel directly applied on the cervix exhibiting high grade CIN lesions;
- evaluating the pharmacokinetic (PK) profile of cidofovir after local application.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1070
- Erasme hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women aged between 18 and 50 years old
- volunteers
- informed consent signed
- cervical lesion classified CIN 2 or 3, on a biopsy made during the 6 preceding weeks
- no sexual activity or use of effective mechanical, hormonal or intrauterine contraception (except hormonal vaginal ring)
Exclusion Criteria:
- pregnancy or breast feeding
- subtotal hysterectomy
- current or ancient renal impairment
- current immune disorder
- current use of drugs interfering with renal function
- current treatment for any cancer
- current use of treatment interfering with immunity
- current use of anti-viral treatment
- current or recent participation to another experimental study during the last 3 months before the screening visit
- current vaginal application of drugs or cosmetics
- local or general condition incompatible with the experimental treatment in the opinion of the principal investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cidofovir
|
topical gel applied once a week for 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
adverse events
Time Frame: weeks 1, 2, 3 and 4
|
weeks 1, 2, 3 and 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michel Bossens, MD, PhD, Erasme Hospital - Laboratoire de recherche en reproduction humaine
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Carcinoma in Situ
- Neoplasms
- Uterine Cervical Neoplasms
- Cervical Intraepithelial Neoplasia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Cidofovir
Other Study ID Numbers
- MI-COL-CI01
- EudraCT2009-012937-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Neoplasms
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyQilu Hospital of Shandong University; Third Military Medical University; Women... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyZhejiang University; Wuhan Central HospitalUnknownCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
Siriwan Tangjitgamol, MDPrince of Songkla University; National Research Council of Thailand; Chiang Mai... and other collaboratorsUnknownUterine Cervical CancerThailand
-
Tampere UniversityGlaxoSmithKline; FinnMedi OyEnrolling by invitation
-
University Hospitals Cleveland Medical CenterCompletedUterine Cervical Dysplasia | Uterine Cervical Cancer | Uterine Cervical Neoplasia | Uterine Cervical Intraepithelial Neoplasia
-
Huazhong University of Science and TechnologyShandong University; Zhejiang UniversityCompletedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
Clinical Trials on Cidofovir gel
-
University of PennsylvaniaCompletedPrevention of Hair GrowthUnited States
-
National Cancer Institute (NCI)Completed
-
National Center for Research Resources (NCRR)Northwestern UniversityCompletedAcquired Immunodeficiency Syndrome | Cytomegalovirus Retinitis
-
Medical University of ViennaUniversity of ViennaCompletedAcute Renal Failure | Cytomegalovirus RetinitisAustria
-
M.D. Anderson Cancer CenterActive, not recruitingTransplantation InfectionUnited States
-
ChimerixCompletedCMVUnited States, Belgium, Canada
-
Hospital Universitari Vall d'Hebron Research InstituteUnknown
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompletedPrecancerous Condition | Anal CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownCervical Cancer | Precancerous ConditionFrance